The efficacy of paclitaxel and cisplatin combination chemotherapy for the treatment of metastatic or recurrent gastric cancer: A multicenter phase II study

Korean Journal of Internal Medicine

Volumn 20, Issue 2, 2005, Pages 135-140

  Shin, Sang Joon ^d   Chun, Sung Ho ^d   Kim, Kyeong Ok ^d   Kim, Min Kyoung ^d   Lee, Kyung Hee ^d   Hyun, Myung Soo ^a,d   Bae, Sung Hwa ^b   Ryoo, Hun Mo ^b   Do, Young Rok ^c   Kwon, Ki Young ^c   Song, Hong Suk ^c  

^a Yeungnam University College of Medicine   (South Korea)

^b Catholic University of Daegu   (South Korea)

^c Keimyung University   (South Korea)

^d Yeungnam University College of Medicine ^*

Author keywords

Paclitaxel; Stomach Neoplasms

Indexed keywords

CIMETIDINE; CISPLATIN; DEXAMETHASONE; PACLITAXEL; SEROTONIN ANTAGONIST; ANTINEOPLASTIC AGENT;

ADULT; AGED; ANEMIA; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CLINICAL ARTICLE; CLINICAL TRIAL; DIARRHEA; DRUG EFFICACY; FEMALE; FOLLOW UP; HUMAN; HYPERSENSITIVITY; KIDNEY DISEASE; LIVER DISEASE; MALE; METASTASIS; MUCOSA INFLAMMATION; MULTICENTER STUDY; NAUSEA; NEUROPATHY; NEUTROPENIA; PHASE 2 CLINICAL TRIAL; RECURRENT CANCER; STOMACH CANCER; SURVIVAL RATE; SURVIVAL TIME; THROMBOCYTOPENIA; VOMITING; DRUG COMBINATION; MIDDLE AGED; PROSPECTIVE STUDY; SAFETY; STOMACH TUMOR; TREATMENT OUTCOME; TUMOR RECURRENCE;

ADULT; AGED; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC AGENTS, PHYTOGENIC; CISPLATIN; DRUG THERAPY, COMBINATION; FEMALE; FOLLOW-UP STUDIES; HUMANS; MALE; MIDDLE AGED; NEOPLASM METASTASIS; NEOPLASM RECURRENCE, LOCAL; PACLITAXEL; PROSPECTIVE STUDIES; SAFETY; STOMACH NEOPLASMS; TREATMENT OUTCOME;

EID: 25144444885     PISSN: 12263303     EISSN: None     Source Type: Journal    
DOI: 10.3904/kjim.2005.20.2.135     Document Type: Article

References (27)

1. Wong JE, Ito Y, Correa P, Peeters KC, van de Velde CJ, Sasako M, Macdonald J. Therapeutic strategies in gastric cancer. J Clin Oncol 21:267s-269s, 2003
2. Macdonald JS, Smalley SR, Benedetti J, Hundahl SA, Estes NC, Stemmermann GN, Haller DG, Ajani JA, Gunderson LL, Jessup JM, Martenson JA. Chemoradiotherapy after surgery compared with surgery alone for adenocardnoma of the stomach or gastroesophageal junction. N Engl J Med 345:725-730, 2001
3. Parker SL, Tong T, Bolden S, Wingo PA. Cancer statistics, 1996. CA Cancer J Clin 46:5-27, 1996
4. Pyrhonen S, Kuitunen T, Nyandoto P, Kouri M. Randomised comparison of fluorouracil, epidoxorubicin and methotrexate (FEMTX) plus supportive care with supportive care alone in patients with non-resectable gastric cancer. Br J Cancer 71:587-591, 1995
5. MacDonald JS, Schein PS, Woolley PV, Smythe T, Ueno W, Hoth D, Smith F, Boiron M, Gisselbrecht C, Brunet R, Lagarde C. 5-Fluorouracil, doxorubicin and mitomycin (FAM) combination chemotherapy for advanced gastric cancer. Ann Intern Med 93:533-536, 1980
6. Cullinan SA, Moertel CG, Fleming TR, Rubin JR, Krook JE, Everson LK, Windschitl HE, Twito DI, Marschke RF, Foley JF. A comparison of three chemotherapeutic regimens in the treatment of advanced pancreatic and gastric carcinoma: fluorouracil vs fluorouracil and doxorubicin vs fluorouracil, doxorubicin, and mitomycin. JAMA 253:2061-2067, 1985
7. Chang YF, Li LL, Wu CW, Liu TY, Liu WY, Peng FK, Chi CW. Paclitaxel-induceu apoptosis in human gastric carcinoma cell lines. Cancer 77:14-18, 1996
8. Matsuoka H, Yano K, Saito T, Seo Y, Tomoda H. Cytotoxicity of paclitaxel in comparison with other anticancer agents against neoplastic cells obtained from clinical gastrointestinal carcinoma tissue. Anticancer Res 15:2001-2006, 1995
9. Cascinu S, Graziano F, Cardarelli N, Marcellini M, Giordani P, Menichetti ET, Catalane G. Phase II study of paclitaxel in pretreated advanced gastric cancer. Anticancer Drugs 9:307-310, 1998
10. Thigpen JT, Blessing JA, Beecham J, Homesley H, Yordan E. Phase II trial of cisplatin as first-line chemotherapy in patients with advanced or recurrent uterine sarcomas. J Clin Oncol 9:1962-1966. 1991
11. Vanhoefer U, Harstrick A, Wilke H, Schleucher N, Walles H, Schroder J, Seeber S. Schedule-dependent antagonism of paclitaxel and cisplatin in human gastric and ovarian carcinoma cell lines in vitro. Eur J Cancer 31A:92-97, 1995
12. Ilson DH, Ajani J, Bhalla K, Forastiere A, Huang Y, Patel P, Martin L, Donegan J, Pazdur R, Reed C, Kelsen DP. Phase II trial of paclitaxel, fluorouracil, cisplatin in patients with advanced carcinoma of the esophagus. J Clin Oncol 16:1826-1834, 1998
13. Khuri FR, Shin DM, Glisson BS, Lippman SM, Hong WK. Treatment of patients with recurrent or metastatic squamous cell carcinoma of the head and neck current status and future directions. Semin Oncol 27:(Suppl 8) 25-33, 2000
14. Gatzemeier U, von Pawel J, Gottfried M, ten Velde GP, Mattson K, DeMarinis F, Harper P, Salvati F, Robinet G, Lucenti A, Bogaerts J, Gallant G. Phase III comparative study of high dose cisplatin versus a combination of paclitaxel and cisplatin in patients with advanced non-small-cell lung cancer. J Clin Oncol 18:3390-3399, 2000
15. Pfisterer J. Optimierung der primären Chemotherapie des fortgeschrittenen Ovarialkarzinoms. Onkologie 23:31-43, 2000
16. Kornek GV, Raderer M, Schull B, Fiebiger W, Gedlicka C, Lenauer A, Depisch D, Schneeweiss B, Lang F, Scheithauer W. Effective combination chemotherapy with paclitaxel and cisplatin with or without human granulocyte colony-stimulating factor and/or erythropoietin in patients with advanced gastric cancer. Br J Cancer 86:1858-1863, 2002
17. Kollmannsberger C, Quietzsch D, Haag C, Lingenfelser T, Schroeder M, Hartmann JT, Baronius W, Hempel V, Clemens M, Kanz L, Bokemeyer C. A phase II study of paclitaxel, weekly, 24-hour continous infusion 5-fluorouracil, folinic acid and cisplatin in patients with advanced gastric cancer. Br J Cancer 83:458-462, 2000
18. Honecker F, Kollmannsberger C, Quietzsch D, Haag C, Schroeder M, Spott C, Hartmann JT, Baronius W, Hempel V, Kanz L, Bokemeyer C. Phase II study of weekly paclitaxel plus 24-h continuous infusion 5-fluorouracil, folinic acid and 3-weekly cisplatin for the treatment of patients with advanced gastric cancer. Anticancer Drugs 13:497-503, 2002
19. Park SR, Oh DY, Kim DW, Kim TY, Heo DS, Bang YJ, Kim NK, Kang WK, Kim HT, Im SA, Suh JH, Kim HK, Kim HK. A multi-center, late phase II clinical trial of Genexol (paclitaxel) and cisplatin for patients with advanced gastric cancer. Oncol Rep 12:1059-1064, 2004
20. Simon R. How large should a phase II trial of a new drug be? Cancer Treat Rep 71:1079-1085, 1987
21. Kaplan EL, Meier P. Non-parametric estimation from incomplete observations. J Am Stat Assoc 53:458-481, 1958
22. Ajani JA, Fairweather J, Dumas P, Patt YZ, Pazdur R, Mansfield PF. A phase II study of Taxol in patients with advanced untreated gastric carcinoma [Abstract]. Proc Annu Meet Am Soc Clin Oncol 16:A933, 1997
23. Ohtsu A, Boku N, Tamura F, Muro K, Shimada Y, Saigenji K, Akazawa S, Kitajima M, Kanamaru R, Taguchi T. An early phase II study of a 3-hour infusion of paclitaxel for advanced gastric cancer. Am J Clin Oncol 21:416-419, 1998
24. Wils J. The treatment of advanced gastric cancer. Semin Oncol 23:397-406, 1996
25. Roth AD, Maibach R, Martinelli G, Fazio N, Aapro MS, Pagani O, Morant R, Borner MM, Herrmann R, Honegger H, Cavalli F, Alberto P, Castiglione M, Goldhirsch A. Docetaxel (Taxotere)-cisplatin (TC): an effective drug combination in gastric carcinoma. Ann Oncol 11:301-306, 2000
26. Ridwelski K, Gebauer T, Fahlke J, Kroning H, Kettner E, Meyer F, Eichelmann K, Lippert H. Combination chemotherapy with docetaxel and cisplatin for locally advanced and metastatic gastric cancer. Ann Oncol 12:47-51, 2001
27. Ajani JA, van Cutsem E, Moiseyenko V, Tjulandin S, Fodor M, Majlis A, Boni C, Zuber E, Blattmann A. Docetaxel (D), cisplatin, 5-fluorouracil compare to cisplatin (C) and 5-fluorouracil (F) for chemotherapy-naive patients with metastatic or locally recurrent, unresectable gastric carcinoma (MGC): interim results of a randomized phase III trial (V325). Proc Am Soc Clin Oncol 22:249, 2003